PSMA-targeted docetaxel (BIND-014) - Pfizer
BIND Therapeutics: Annual Report 2015 (BIND Therapeutics) - Mar 18, 2016 - Anticipated expiry of issued patents between 2025 and 2030; Anticipated expiry of pending patents between 2028 and 2035 
Anticipated patent expiry • Oncology
http://ir.bindtherapeutics.com/financials.cfm
 
Mar 18, 2016
 
.